News

A stem cell transplant was found to be better than Lemtrada (alemtuzumab) for lowering disease activity and slowing disability worsening in people with highly active relapsing forms of multiple sclerosis (MS), a small study in Lithuania showed. While both treatments were similarly effective in the first couple of…

Targeting genes that control the daily activity cycle of cells that are responsible for repairing myelin in the brain and spinal cord may be a useful strategy for treating multiple sclerosis (MS), a new study shows. Findings also point to a potential link between myelin disorders such as MS…

People with multiple sclerosis (MS) of African descent had higher levels of inflammatory B-cells in the fluid around the brain and spinal cord compared with white MS patients in a small U.S. study. These findings may help to explain why Black people with MS tend to experience a faster…

More activity among certain immune cells, as well as differences in immune signaling molecules, iron regulation, and fat metabolism, may explain why multiple sclerosis (MS) progresses more over time in some people than in others, researchers report. These findings may help to better understand the molecular mechanisms leading to…

People with a higher genetic risk for multiple sclerosis (MS) were seen to have detectable differences in their gut bacteria in a small study. “There seems to be an association between genetic risk score and [changes in gut bacteria] in triggering the disease in a small cohort of MS…

In children with pediatric-onset multiple sclerosis (POMS), poor sleep quality is linked to fatigue, depression, and worse quality of life, a study has found. While no significant differences in sleep measures were identified between children and adolescents with MS compared with those without the neurodegenerative condition, sleep can have…

Achieving NEDA — no evidence of disease activity — after two years of treatment was not common among people with relapsing-remitting multiple sclerosis (RRMS) at a center in Italy. NEDA more often was reached, however, when researchers didn’t include the first few months of treatment in their analysis, suggesting…

Combining a saffron supplement and an exercise program for three months was seen to significantly ease depression and improve quality of life for women with multiple sclerosis (MS), a study in Iran found. The combination of the two treatments worked better than either approach alone. “Although … the corrective…

A scoring system that accounts for relapses and MRI activity in multiple sclerosis (MS) patients during their first year on an oral disease-modifying therapy (DMT) was found to be predictive of worse short-term outcomes for people with relapsing forms of the neurodegenerative disorder, a study showed. “The occurrence of…

The most common real-world side effects linked to dalfampridine — sold as Ampyra and with generics available — are similar to those listed on its prescribing label for multiple sclerosis (MS), according to data from a safety surveillance database. Common side effects included urinary tract infection (UTI), dizziness…

A patient’s ability to cope with and recover from adversity — called psychological resilience — was found to impact the observed relationship between fear of relapse and life quality among people with multiple sclerosis (MS) in a new study. Essentially, MS patients who had…

Losing the sense of smell is associated with a higher likelihood of worse disease outcomes for people with multiple sclerosis (MS), according to a six-year follow-up study. Specifically, patients who are getting worse at identifying and discriminating odors are at higher risk of disability worsening, relapse-independent MS progression, and…

Neural Sleeve, a bionic piece of clothing by Cionic designed to help with walking and strength, is among the 200 devices on Time magazine’s annual list of best inventions, under its accessibility category. The lightweight, leg-worn device, which combines continuous motion analysis with functional electrical stimulation,…

Low blood levels of vitamin D are tied to poorer cognitive skills and more severe disability in people with multiple sclerosis, researchers in Italy report. “Our study showed that [vitamin D] levels are associated with cognitive function in MS, as already well demonstrated in the general population and in…

Experiencing certain stressors during childhood may predict the future presence and severity of fatigue, pain, and psychiatric conditions associated with multiple sclerosis (MS), according to a new U.S. study. Childhood physical and emotional stressors were each significantly linked to a higher likelihood of MS patients experiencing each of the…

Cionic, the neurotech company that developed Neural Sleeve to help people who have problems with mobility, has raised an additional $12 million extension in a Series A financing, bringing the total funding for the garment to $25 million. The funds will help grow the sleeve’s adoption among people with…

In a surprise discovery, researchers found that deleting a protein called integrin alpha-3 blocked harmful immune cells from accessing the brain — and prevented the onset of symptoms — in a mouse model of multiple sclerosis (MS). Now, the researchers say that targeting this protein might be one way…

Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to severe spasticity in adults with multiple sclerosis (MS) in Ireland who failed to respond as intended to other spasticity medications. Marked by muscle stiffness and involuntary spasms or twitches,…

The overall financial impact of changes in treatment and delayed diagnoses for people with multiple sclerosis (MS) in Canada due to the COVID-19 pandemic likely will be in the hundreds of millions of dollars between 2020 and 2024 in terms of extra healthcare costs and lost productivity, as well…

Brain atrophy (shrinkage) in people with multiple sclerosis (MS) begins on average more than five years before disease symptoms appear, according to a new study based on machine learning models. “Although the onset of progressive brain tissue loss measured by MRI is not synonymous with the true biological…

Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six people with nonactive secondary progressive multiple sclerosis (SPMS) involved in an expanded access program. Microglia are resident immune cells in the brain believed to play a role in driving…

More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the RADIANCE clinical trial and its extension study still haven’t experienced confirmed disability progression after eight years of follow-up, new data shows. Among those who progressed, about half of disability progression…

New research by scientists in Austria may shed light on the link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), and explain why only some people infected with EBV — previously found to raise the risk of MS by 32 times — go on to develop the neurodegenerative disorder. Distinct…

The risk of converting to secondary-progressive multiple sclerosis (SPMS) has declined in recent years for patients who have an earlier disease onset, an analysis of data from the Swedish MS Registry indicates. The conversion is also occurring later in life and in people who have lived with multiple…

Multiple sclerosis (MS) patients had significantly more sickness-related work absences in the years leading up to their disease onset than people in the general population, a recent Swedish analysis showed. Scientists believe the findings support the growing notion that there is an MS prodrome, during which early signs of…

Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or two prior to disability worsening in people with multiple sclerosis (MS), particularly among patients whose disease progressed without any relapse activity. That’s according to new data presented at the…

Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly if given in early disease stages when disabling symptoms are negligible. That’s according to data shared at the 9th joint meeting of the European Committee for Treatment and…

Treatment with the investigational therapy fenebrutinib significantly reduced the number of new inflammatory lesions visible on MRI scans in people with relapsing forms of multiple sclerosis (MS). Pharmacological data from the study suggest the anti-inflammatory experimental medication can get into the brain and spinal cord at levels high…

Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS), according to new data from the long-term safety (LTS) extension of a Phase 2b trial. The data…

Obese people with multiple sclerosis (MS) had faster disability accumulation, greater cognitive declines, and worse quality of life in the 15 years after diagnosis relative to patients with normal weight, according to an analysis of Swedish data. While it’s been known that obesity was a risk factor for developing…